Skip to main
TYRA
TYRA logo

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences Inc is positioned favorably due to its innovative in-house precision medicine platform, SNAP, which enhances the design and prediction of high-potency drug candidates, exemplified by its clinical-stage molecule TYRA-300. The company is set for a significant development period in 2025, with multiple indications for TYRA-300 expected to advance, thereby expanding its pipeline and enhancing potential revenue streams. The clearance of trials for lower doses of TYRA-300 further supports the company’s strategy to address various medical needs, thereby increasing the likelihood of successful therapeutic outcomes and potential market impact.

Bears say

Tyra Biosciences reported a significant net loss of $25.6 million, equating to a loss of $0.43 per share, which closely aligns with prior estimates, indicating potential ongoing financial struggles. The clinical pipeline faces considerable risk, particularly with reliance on the success of TYRA-300, alongside concerns of clinical and regulatory setbacks that could adversely affect revenue projections if the product receives approval. Furthermore, data from competing pan-FGFR inhibitors demonstrate noteworthy safety and efficacy challenges, highlighting the competitive landscape and potential hurdles for the company’s drug candidates, which may further undermine investor confidence.

Tyra Biosciences (TYRA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.